Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates.

Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including Corynex® protein expression technology, oligonucleotide synthesis, antibody-drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs.

Ajinomoto Bio-Pharma Services recognizes that sustainable and safe development is necessary to secure the future of our company. In all of our activities, we consider the impact of our manufacturing processes to the health and safety of our employees on the environment. We strive to provide our customers with innovative solutions and promote the implementation of environmentally responsible process and technologies, and are committed to meeting our energy and water reduction targets by 2030.


17 November 2020